CMPS Is Rallying on a 'Launch-Prep' Narrative — Approval Still Hinges on the Gates Ahead

Compass Pathways (CMPS) is rallying again — shares were up about 5% in regular trading Monday and more after hours — and the stated reason is a "launch-prep push" ahead of a Food and Drug Administration psychedelics hearing scheduled for Monday, September 14. The company is debuting a U.S. doctor-education campaign, presenting new health-economics data, and putting management on stage at an investor conference, and the market is reading all of it as a signal that approval is near.

The instinct is understandable, but it leans on a false narrative worth testing. Launch prep measures how fast Compass could commercialize psilocybin therapy if it wins approval. It says almost nothing about whether it wins approval. And the particular FDA event everyone is watching this week is not a ruling on Compass at all.

This is a stock that investors should understand as a probability bet on a chain of regulatory events, not a business with cash being returned to them. On that measure, it is worth keeping the gates straight.

What the rally is actually trading on

Start with where the price already sits. CMPS is up roughly 130% over the last four months and more than doubled year to date, trading around $14, just below its 52-week high of $15.40 and far above its low of $4.82. Monday's move is the continuation of a run that began months ago, before any of this week's announcements.

The specific signals driving the day: the debut of a physician-education campaign called "Change the Tune in TRD" at Psych Congress in New Orleans this week, new cost-of-illness data for treatment-resistant depression, and management appearances at the Cantor Global Healthcare Conference — a fireside chat and a panel on accessing "the new wave of psychedelics." A rolling FDA application is already underway, with the full package due in the fourth quarter.

The hearing that isn't an approval review

The cleanest test of the narrative is the FDA event the headlines point to. On Monday, September 14, from 12:30 to 4:30 p.m. ET, the agency holds a public hearing on the future therapeutic use of psychedelic drugs in supervised settings, seeking comment on provider training, patient safety, access, and data standards. It is not a review of any pending application. It does not rule on COMP360.

That distinction matters. The market often treats a "psychedelics hearing" as an advance on a specific approval. Here, it is a broad listening session about how the agency might approach a whole class of therapies someday. An education campaign and a comment-gathering hearing are real events; neither moves the FDA one step closer to approving Compass's drug.

The gates that actually stand between $14 and a product

The value of the company rests on a chain of decisions, each of which can break:

• The filing. Compass's rolling NDA is due to be completed in the fourth quarter of 2026. Under a Commissioner's National Priority Voucher awarded in April, a finished application could get a compressed one-to-two-month priority review.
• The FDA verdict. Approval of COMP360 — a synthetic psilocybin given as psychedelic-assisted therapy, typically one or two supervised sessions — rests on two positive Phase 3 trials in treatment-resistant depression, with effects reported as early as one day and durability through six months.
• The DEA decision that is easy to miss. A U.S. launch also requires the Drug Enforcement Administration to reschedule psilocybin out of Schedule I so it can be lawfully prescribed. That is an independent federal step the FDA does not control.
• Reimbursement. This is not a pill you pick up at a pharmacy. It is therapy administered in a supervised setting by trained providers — which is exactly why Compass is spending on education and training now, and also why both the cost base and the coverage questions are larger than a conventional drug's. Reimbursement is unproven.

The numbers behind the story

Here is where the persona's usual bedrock — free cash flow and dividends — does not exist yet, and saying so matters. Compass has no product revenue, pays no dividend, and is burning cash. It held about $433 million at the end of June, which management says funds operations into 2028, against roughly $161 million in trailing free cash flow used. Its second-quarter net loss widened to $1.88 a share from $0.41 a year earlier, most of it a $205.6 million non-cash fair-value loss on warrants, with operating expenses also climbing as launch preparation ramps.

Against that, the market values the whole enterprise at roughly $1.9 billion in market capitalization — about $1.6 billion in enterprise value once its cash is backed out. Every dollar of that rest on an unapproved product clearing the chain above. The warrant-driven loss is a reminder that this company is financed, in part, by instruments whose value swings with the stock price, not by earnings.

What would change the conclusion

None of this argues Compass will fail, and two clean Phase 3 wins in a notoriously hard indication are genuine. But it argues the current rally is priced on expectation, and that this week's marketing calendar and next week's hearing say more about excitement than about the odds.

The condition that would change my read is the one the current headlines cannot supply: the completed NDA going in during the fourth quarter, an actual FDA decision, and the DEA's separate rescheduling call — followed by evidence that payers will cover supervised psychedelic therapy. Until those links close, the launch-prep push is best understood as noise around a stock that has already run far, not as a reason to chase it. In my opinion, the investable question for a new holder is not what Compass is doing at a conference; it is whether the approval chain that still stands ahead is already priced at $14.